Table 1.
Antimicrobial susceptibilities of 62 Salmonella Choleraesuis isolates from clinical specimens.
| Antimicrobial | Group | % Resistant (Isolate) | % Intermediate (Isolate) | % Sensitive (Isolate) |
|---|---|---|---|---|
| AMP | penicillin | 100 (62) | 0 | 0 |
| AMC | β-lactam/β-lactam inhibitor combination | 43.4 (30) | 0 | 51.6 (32) |
| ATM | monobactam | 43.5 (27) | 12.9 (8) | 43.5 (27) |
| FEP | cephalosporin | 8.1 (5) | 21.0 (13) | 71.0 (44) |
| CAZ | cephalosporin | 62.9 (42) | 6.4 (4) | 25.8 (16) |
| FOX | cephalosporin | 40.3 (25) | 4.8 (3) | 54.8 (34) |
| CTX | cephalosporin | 100.0 (62) | 0 | 0 |
| CPD | cephalosporin | 98.4 (61) | 0 | 0 |
| KF | cephalosporin | 100 (62) | 0 | 0 |
| CXM | cephalosporin | 80.6 (53) | 12.9 (8) | 1.6 (1) |
| CRO | cephalosporin | 100.0 (62) | 0 | 0 |
| EFT | cephalosporin | 96.8 (60) | 3.2 (2) | 0 |
| CIP | fluoroquinolone | 14.6 (9) | 67.7 (42) | 17.7 (11) |
| CHL | phenicol | 83.9 (52) | 9.7 (6) | 6.4 (4) |
| NA | quinolone | 100.0 (62) | 0 | 0 |
| NOR | fluoroquinolone | 0.0 (0) | 0 | 100 (62) |
| S | aminoglycoside | 64.5 (43) | 19.3 (12) | 11.3 (11) |
| TET | tetracycline | 100.0 (62) | 0 | 0 |
| STX | folate Pathway inhibitor | 11.3 (7) | 1.61 (1) | 87.1 (54) |
AMP, ampicillin; AMC, amoxicillin + clavulanate; CIP, ciprofloxacin; NA, nalidixic acid; ATM, aztreonam; CHL, chloramphenicol; S, streptomycin; TET, tetracycline; SXT, sulfamethoxazole; KF, cefalothin; FOX, Cefoxitin; FEP, cefepime; CXM, cefuroxime; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; CPD, cefpodoxime; EFT, ceftiofur.